治験一覧
8,963 件中 181〜200 件を表示
尋常性乾癬の小児および10代の若者を対象としたザソシチニブの長期試験
The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it. The study will be done in 2 parts: Part A will include both children and teenagers, while part B will only include children. At first, only teenagers who meet the study rules can participate in this study. Children may only start to participate once enough information has been collected from other studies with zasocitinib. Participants in Part A will initially be assigned to receive either zasocitinib or placebo for the first 16 weeks of treatment, then all participants will receive zasocitinib through the end of the study. All participants in Part B will be assigned to receive treatment with zasocitinib throughout the study. Participants will be in the study for up to 4 years and 2 months (217 weeks), including up to 35 days for the screening period, 208 weeks of treatment (Part A and Part B) and a 4-week safety follow-up period. During the study, participants will visit their study site multiple times.
アルツハイマー病研究の試験適格性を有する可能性のある個人を決定するためのスクリーニング研究
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
中大脳動脈M2部閉塞を伴う急性虚血性脳卒中に対する血管内治療のランダム化臨床試験
RESCUE-M2O trial is a prospective, open label, blinded endpoint (PROBE), two-arm, randomized, controlled, post-market study to assess the efficacy and safety of endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.
高血圧および肥満または過体重の参加者を対象としたオルフォルグリプロン（LY3502970）のマスタープロトコル試験（ATTAIN-Hypertension）GZL1
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
シトリン欠損症におけるマルチオミクス研究
Citrin deficiency (CD) is an underdiagnosed and understudied condition characterized by several distinct phenotypes: 1) neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), 2) the adaptation or silent period, 3) "failure to thrive and dyslipidemia" form of CD (FTTDCD), and 4) citrullinemia type II (CTLN2), with the latter representing the final and most severe form of the condition. There is currently no cure for CD and patients manage their symptoms with lifelong dietary intervention and regular checkups with their physicians. A major hurdle in developing effective treatments for CD is the lack of effective biomarkers that track well with disease severity or measure the effectiveness of therapeutics. The present study aims to identify robust circulating biomarkers of CD through analysis of blood samples from CD patients.
生物学的製剤使用経験のある活動性乾癬性関節炎患者におけるイコトロキンラ（JNJ-77242113）の有効性と安全性を評価する試験
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
高血圧および肥満または過体重の参加者におけるオルフォルグリプロン（LY3502970）のマスタープロトコル：（ATTAIN-高血圧スクリーニング）
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.
日本で第3相試験を完了した慢性ITPの成人患者に対するリルザブルチニブ
This is an open-label, multi-center, single group, Phase 3 study for treatment with rilzabrutinib. The purpose of this study is to provide continuation of rilzabrutinib treatment to adult participants with ITP who have completed the LTE of the LUNA 3 study in Japan, demonstrating clinically meaningful benefit as judged by the Investigator.
転移性前立腺癌の日本人患者を対象としたJSB462（ルクスデガルタミド）の第I相試験
This Phase I study aims to evaluate the safety, tolerability and PK of JSB462 in Japanese patients with metastatic prostate cancer.
子宮頸がんにおけるアジア婦人科小線源治療登録
Gynecological cancer poses as significant public health issue, especially in Asian countries, where it is a leading cause of cancer-related deaths among women. Cervical cancer accounts for around 311,000 deaths annually, with over 85% occurring in low- and middle-income nations, primarily in Asia. Factors contributing to this burden include limited access to preventive care, inadequate screening, high rates of human papillomavirus infection, and cultural barriers that delay medical attention. For patients with advanced cervical cancer, the standard treatment involves external beam radiation therapy along with chemotherapy followed by internal radiation, known as Brachytherapy. This technique uses unique set of devices placed internally at the tumor sitegiving localized radiation to the residual tumor tissue. While advanced brachytherapy techniques have been developed and practiced in Europe and American countries yielding excellent clinical outcomes, there is insufficient data on the use and results of such advanced brachytherapy techniques in Asian populations, leading to a lack of standardized practices. To address these issues, the Asian Gynecological Brachytherapy Registry (ABGR) has been established as a collaborative platform for data collection and analysis on the use of Brachytherapy techniques. This registry aims to consolidate information from various healthcare settings across Asia, enhancing understanding of cervical cancer's epidemiology, evaluating treatment effectiveness, and identifying areas for improvement in patient care.
新潟県における心血管疾患患者の予後予測に関する研究
The goal of this observational study is to investigate the prognosis of cardiovascular disease in Niigata Prefecture. Specifically, it aims to clarify the current status of medical treatment for cardiovascular disease patients in regional cities in Japan, where the population is aging. With patient consent, the study will track long-term medical treatment progress using health insurance claim data recorded in Japan's unique social security system.
免疫グロブリンA腎症（IgAN）の成人患者に対するフェルザルタマブ点滴の効果を調べる研究
In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). This study will focus on participants who have protein in their urine (proteinuria) as a result of damaged kidneys. The main goal of the study is to learn about the effect felzartamab has on proteinuria. The main question that researchers want to answer is: • How much does the amount of protein in the urine change from the start of the study to Week 36? Researchers will learn about the effect felzartamab has on the kidneys' ability to filter blood. They will also learn more about the safety of felzartamab and how it is processed by the body. The study will be done as follows: * Participants will be screened to check if they can join the study. * Participants will be randomized to receive either felzartamab or a placebo. A placebo looks like the study drug but contains no real medicine. * Neither the researchers nor the participants will know what the participants will receive. * Participants will receive felzartamab or placebo as intravenous (IV) infusions. The treatment period will last 24 weeks. * Afterwards, participants will enter a follow-up period which will last 80 weeks. * In total, participants will have 17 study visits. Participants will stay in the study for about 2 years.
ラクナ梗塞の超急性期における新規アプローチレジメンの臨床利用：Rt-PA vs. DAPTランダム化臨床試験
この臨床試験の目的は、小規模虚血性脳卒中（ラクナ脳卒中）の治療において、抗血小板薬の併用が静脈内組織プラスミノーゲンアクチベーター投与よりも有効かどうかを明らかにすることです。主な疑問は以下のとおりです。 抗血小板薬の併用は、現在の標準的な組織プラスミノーゲンアクチベーター治療に非劣性であるか？抗血小板薬の併用は、組織プラスミノーゲンアクチベーター投与よりも出血性合併症を軽減するか？ 研究者らは、抗血小板薬の併用が小規模虚血性脳卒中（ラクナ脳卒中）の治療に有効かどうかを調べるため、抗血小板薬の併用と組織プラスミノーゲンアクチベーター投与を比較します。 参加者は以下のことを行います。 抗血小板薬の併用または静脈内組織プラスミノーゲンアクチベーター投与を受ける。脳卒中後3ヶ月で、対面、電話、または郵送で神経学的状態を確認します。
アルツハイマー病における認知機能障害に対するKarXT + KarX-ECの有効性と安全性を評価する研究（MINDSET 2）
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
CIDPの成人患者におけるエンパシプルバートとIVIgの有効性と安全性を評価する研究
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months).
転移性前立腺癌患者におけるAZD0516の単剤療法および併用療法の研究
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
原発性IgANの小児患者におけるイプタコパンの有効性、薬物動態、安全性および忍容性を評価する研究
The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (including CV surveillance) of iptacopan in primary immunoglobulin A nephropathy (IgAN) pediatric patients aged 2 to \<18 years.
連合連携臨床ケア現場におけるヒューマノイドロボットの導入と評価
This clinical trial evaluates the deployment of humanoid robotics in coalition-aligned healthcare settings. The study measures biometric performance, ESG compliance, and operational impact across patient care, sanitation, and intake workflows. Humanoid units are enhanced via biotech integration and compensated through blockchain-based wage tokens. Outcomes will inform coalition governance, wage calibration, and metro-scale deployment strategies.
中等度から重度の尋常性乾癬におけるESK-001の長期安全性と有効性
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study. Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis. Patients must consent and agree to: * ensure drug daily compliance until end of study or discontinuation. * visit the clinic for checkups and assessments. * provide blood and urine samples.
試験食品摂取による睡眠改善効果の検証研究
The goal of this clinical trial is to test in Japanese adults who feel sleepy when they wake up. The question it aims to answer are: •Does taking plasmalogens reduce sleepiness upon waking? Participants will be given the following tasks: * Take 4 capsules daily containing plasmalogens for 12 weeks. * Answer the questionnaire on sleepiness1 when they wake up. * Answer the questionnaire on daytime sleepiness2. Researchers will compare plasmalogens and placebo groups to see if plasmalogens reduce sleepiness upon waking.